Team:MIT/Safety

From 2014.igem.org

(Difference between revisions)
Line 3: Line 3:
<html>
<html>
-
<head></head>
 
-
<body>
 
-
 
-
<!--main content -->
 
-
<table width="70%" align="center">
 
-
 
-
 
-
<!--welcome box -->
 
-
<tr>
 
-
<td style="border:1px solid black;" colspan="3" align="center" height="150px" bgColor=#148282>
 
-
<h1 style="color:#E7E7E7">MIT iGEM 2014</h1>
 
-
<p style="color:#E7E7E7">Our wiki is currently under construction, so please bear with us as we continue to update it over the coming weeks.
 
-
</p>
 
-
<br>
 
-
<p style="color:#E7E7E7"> <a href="https://2014.igem.org/wiki/index.php?title=Team:MIT/Safety&action=edit"style="color:#FFFFFF"> Click here  to edit this page!</a> </p>
 
-
</td>
 
-
</tr>
 
-
 
-
<tr> <td colspan="3"  height="5px"> </td></tr>
 
-
<!-- end welcome box -->
 
-
<tr>
 
-
 
-
<!--navigation menu -->
 
-
<td align="center" colspan="3">
 
-
 
-
<table  width="100%">
 
-
<tr heigth="15px"></tr>
 
-
<tr heigth="75px">
 
-
 
-
 
-
<td style="border:1px solid black;" align="center" height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7> 
 
-
<a href="https://2014.igem.org/Team:MIT"style="color:#000000">Home </a> </td>
 
-
 
-
<td style="border:1px solid black;" align="center" height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://2014.igem.org/Team:MIT/Team"style="color:#000000"> Team </a> </td>
 
-
 
-
<td style="border:1px solid black;" align="center"  height ="45px"  onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://igem.org/Team.cgi?year=2014&team_name=MIT"style="color:#000000"> Official Team Profile </a></td>
 
-
 
-
<td style="border:1px solid black" align="center"  height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7> 
 
-
<a href="https://2014.igem.org/Team:MIT/Project"style="color:#000000"> Project</a></td>
 
-
 
-
<td style="border:1px solid black;" align="center"  height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://2014.igem.org/Team:MIT/Parts"style="color:#000000"> Parts</a></td>
 
-
 
-
<td style="border:1px solid black;" align="center" height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://2014.igem.org/Team:MIT/Modeling"style="color:#000000"> Modeling</a></td>
 
-
 
-
<td style="border:1px solid black;" align="center" height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7> 
 
-
<a href="https://2014.igem.org/Team:MIT/Notebook"style="color:#000000"> Notebook</a></td>
 
-
 
-
<td style="border:1px solid black;" align="center"  height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://2014.igem.org/Team:MIT/Safety"style=" color:#000000"> Safety </a></td>
 
-
 
-
<td style="border:1px solid black;" align="center"  height ="45px" onMouseOver="this.bgColor='#d3d3d3'" onMouseOut="this.bgColor='#e7e7e7'" bgColor=#e7e7e7>
 
-
<a href="https://2014.igem.org/Team:MIT/Attributions"style="color:#000000"> Attributions </a></td>
 
-
 
-
 
-
<td align ="center"> <a href="https://2014.igem.org/Main_Page"> <img src="https://static.igem.org/mediawiki/igem.org/6/60/Igemlogo_300px.png" width="55px"></a> </td>
 
-
</tr>
 
-
</table>
 
-
<!--end navigation menu -->
 
-
</tr>
 
-
</tr>
 
-
</td>
 
-
 
-
<tr> <td colspan="3"  height="15px"> </td></tr>
 
-
<tr><td bgColor="#e7e7e7" colspan="3" height="1px"> </tr>
 
-
<tr> <td colspan="3"  height="5px"> </td></tr>
 
-
 
-
 
-
<!--safety content-->
 
-
 
-
<tr><td > <h3> This has requirements, in addition to those, We need to come up with answers for how altering the chromosomal DNA of Neurons is safe, because it looks very unsafe (it probably is).  One of the teams sending out a survey was looking into replicons, possible collaboration there.  We will need to mention that we should have a cell profiler and will point mutate what we can to prevent accidental transduction of unrelated signal pathways.
 
-
<br />BCR has bioterror early warning applications, maybe worth mentioning (Unless its a state secret) </h3></td>
 
-
<tr><td > <h3> Welcome! </h3></td>
 
-
<td ></td >
 
-
<td > <h3> Timeline</h3></td>
 
-
</tr>
 
-
 
-
<tr>
 
-
<td width="45%"  valign="top">
 
-
<p> Visit the <a href="https://2014.igem.org/Safety" >Safety Hub</a> to see this year's safety requirements. The Safety Hub is the central page for everything related to safety in iGEM. You can also go there to learn about general biosafety topics, and how to think about the future implications of your project.</p>
 
-
 
-
 
-
 
-
<br>
 
-
<h3> Edit this page!</h3>
 
-
<p>
 
-
Please use this page to write about anything related to safety in your project. <!--Be sure to talk about both
 
-
<ul>
 
-
<li> <a href=" ">Learn about lab Safety for Today</a></li>
 
-
<li> <a href="">Learn about Safety for the future of your project.</a></li>
 
-
</ul>
 
-
-->
 
-
</p>
 
-
 
-
<h3> Your Lab </h3>
 
-
 
-
 
-
<p> Use this section to tell us about your laboratory. Where is it located? What sort of equipment do you use every day? Have you decorated it for the summer? How do you look wearing a lab coat? Take pictures! Show off your space! </p>
 
-
<!--
 
-
<gallery>
 
-
Image:Example2_Lab_1.png|The building our lab is in!
 
-
Image:Example2_Lab_2.png|The inside of our lab!
 
-
Image:Example2_Lab_3.png|Team Member 3 doing an experiment
 
-
Image:Example2_Lab_4.png|Working in biosafety cabinets
 
-
Image:Example2_Lab_5.png|Team all gloved up and ready for work!
 
-
Image:Example2_Lab_6.png|Equipment that we use to do SCIENCE!
 
-
Image:Example2_Lab_7.png|We decorated this part of our lab
 
-
Image:Example2_Lab_8.png|Whatever else you want
 
-
</gallery>-->
 
-
 
-
</td>
 
-
<td></td>
 
-
 
-
 
-
<td width="45%"  valign="top">
 
-
 
-
 
-
<ul>
 
-
<li> <b>Now :</b>  Read the <a href="https://2014.igem.org/Safety">Safety Hub </a> and learn about safety in iGEM. Ask questions by emailing safety at <i> igem DOT org </i>. </li>
 
-
<li><b>Now - Jamboree:</b> Complete <b>Check-Ins</b> and receive approval before acquiring and using certain materials in your lab</li>
 
-
<li><b>Now - Wiki Freeze:</b> Edit this Safety page to tell us about what you're doing</li>
 
-
<li><b>June 9: </b>Submit the About Our Lab form.</li>
 
-
<li><b>Let us know by June 25 </b>if you will need an extension on the Preliminary Version, or your Preliminary Version will be significantly incomplete.</li>
 
-
<li><b>June 30: </b>Submit the Preliminary Version of the <b>Safety Form</b>.</li>
 
-
<li>Participate in Virtual Open Office Hours to ask questions and discuss safety topics (exact date to be determined).</li>
 
-
<li><b>September 1:</b> Submit the Final Version of the Safety Form.</li>
 
-
<li><b>October: </b> Wiki freeze (exact date to be determined)</li>
 
-
<li><b>October 30 - November 3: </b>GIANT JAMBOREE!</li>
 
-
 
-
</ul>
 
-
</td>
 
-
 
-
</tr>
 
-
 
-
 
-
 
-
 
-
<tr>
 
-
 
 +
<table width="90%" align="center">
 +
<tr><td> <h3 align="center" style="font-size:45px"> Safety </h3><br></td></tr>
 +
<tr><td><h1 style="font-size:15px"> Laboratory Safety </h1></td></tr>
 +
<tr><td><p>
 +
Over the past few months, our team worked primarily with BL1 materials (such as E. coli cultures used for cloning) and some BL2 materials (including human cell lines such as HEK293, HeLa, and Ramos).  All students received training through MIT’s Environment Health and Safety (EHS) office in General Biosafety for Researchers, Managing Hazardous Waste, and General Chemical Hygiene, as well as lab-specific training.  Students that worked with BL2 agents received additional blood-borne pathogens training.  We also communicated regularly with our designated EHS representative to ensure that we followed proper safety precautions, including meeting relevant local and national safety standards.
 +
</p></tr></td>
 +
<tr><td><p>
 +
To keep ourselves and our samples safe, we wore proper personal protective equipment (in the form of gloves and a lab coat, as well as eyewear when necessary) at all times in the lab.  Additionally, specially designated tissue culture lab coats were worn when working with mammalian cell lines, which were handled in biosafety cabinets for safety and sterility purposes.  Laboratory chemicals were handled in accordance with the information on their MSDS.  Furthermore, nucleic acids were introduced into mammalian cells using lipofection-based transient transfections rather than viral infection, since this was determined to pose less of a safety threat.
 +
</p></tr></td>
 +
<tr><td><h1 style="font-size:15px"> Biological Parts </h1></td></tr>
 +
<tr><td><p>
 +
The most hazardous biological parts that we worked with during iGEM were siRNAs and plasmids encoding miRNAs against human proteins.  We used siRNAs to test our miRNA profile detection mechanism.  Since we were unable to find a cell line that had the same miRNA profile as that associated with Alzheimer’s disease, we transfected relevant siRNAs into mammalian (HEK293) cells to simulate the presence of the appropriate miRNAs.  Whereas our miRNA project involved the use of siRNAs for testing, our approach to treatment required designing miRNA generators.  We constructed miRNA generators to produce miRNAs to downregulate BACE1, an enzyme involved in the production of beta-amyloid.  In order to affect expression of this endogenous protease, we decided to use a miRNA-based strategy because it could directly affect BACE1 levels in the relevant cells.  Though both these siRNAs and miRNAs could have harmful health effects if they became inserted in human cells, the likelihood of this happening (especially given that proper personal protective equipment was used) was determined to be low enough so as to not pose any significant safety risks.
 +
</p></tr></td>
 +
<tr><td><h1 style="font-size:15px"> Future Implications </h1></td></tr>
 +
<tr><td><p>
 +
In addition to the physical materials that we used and the parts that we engineered, the technologies that we developed also have important safety implications.  Our designed system to detect and treat Alzheimer’s disease would best serve patients if it were introduced using gene therapy, since it involves detecting endogenous miRNAs and downregulating an endogenous enzyme (BACE1).  However, gene therapy techniques such as viral vector or liposome-mediated delivery can result in serious medical complications, and other mechanisms for introducing novel genetic material into cells, such as ex vivo manipulation, also carry serious risks.  Given the severity of Alzheimer’s disease and the lack of suitable treatment options for this condition, a genetic approach like ours still has the potential to improve patient outcomes and could be considered for implementation, as long as these safety concerns are taken into consideration.
 +
</p></tr></td>
 +
<tr><td><h1 style="font-size:15px"> Improving Biosafety with Our Synthetic B-Cell Receptor </h1></td></tr>
 +
<tr><td><p>
 +
The antibody-based sensor (synthetic B-cell receptor) that we developed to detect beta-amyloid plaques could be modified to sense other biologically relevant molecules, including those that pose a biosafety risk.  By interchanging the receptor’s variable region, our sensor could be altered to detect any antigen for which there is an antibody with a known amino acid sequence.  Given that our system could also be modified to produce many different types of outputs (in addition to the transcriptional activator GAL4VP16), a synthetic B-cell receptor could be of great utility for biosafety purposes and more generally as a synthetic biology tool.
 +
</p></tr></td>
 +
<tr><td><br></tr></td>
</table>
</table>
</html>
</html>

Revision as of 20:51, 16 October 2014

 


Image Map


Safety


Laboratory Safety

Over the past few months, our team worked primarily with BL1 materials (such as E. coli cultures used for cloning) and some BL2 materials (including human cell lines such as HEK293, HeLa, and Ramos). All students received training through MIT’s Environment Health and Safety (EHS) office in General Biosafety for Researchers, Managing Hazardous Waste, and General Chemical Hygiene, as well as lab-specific training. Students that worked with BL2 agents received additional blood-borne pathogens training. We also communicated regularly with our designated EHS representative to ensure that we followed proper safety precautions, including meeting relevant local and national safety standards.

To keep ourselves and our samples safe, we wore proper personal protective equipment (in the form of gloves and a lab coat, as well as eyewear when necessary) at all times in the lab. Additionally, specially designated tissue culture lab coats were worn when working with mammalian cell lines, which were handled in biosafety cabinets for safety and sterility purposes. Laboratory chemicals were handled in accordance with the information on their MSDS. Furthermore, nucleic acids were introduced into mammalian cells using lipofection-based transient transfections rather than viral infection, since this was determined to pose less of a safety threat.

Biological Parts

The most hazardous biological parts that we worked with during iGEM were siRNAs and plasmids encoding miRNAs against human proteins. We used siRNAs to test our miRNA profile detection mechanism. Since we were unable to find a cell line that had the same miRNA profile as that associated with Alzheimer’s disease, we transfected relevant siRNAs into mammalian (HEK293) cells to simulate the presence of the appropriate miRNAs. Whereas our miRNA project involved the use of siRNAs for testing, our approach to treatment required designing miRNA generators. We constructed miRNA generators to produce miRNAs to downregulate BACE1, an enzyme involved in the production of beta-amyloid. In order to affect expression of this endogenous protease, we decided to use a miRNA-based strategy because it could directly affect BACE1 levels in the relevant cells. Though both these siRNAs and miRNAs could have harmful health effects if they became inserted in human cells, the likelihood of this happening (especially given that proper personal protective equipment was used) was determined to be low enough so as to not pose any significant safety risks.

Future Implications

In addition to the physical materials that we used and the parts that we engineered, the technologies that we developed also have important safety implications. Our designed system to detect and treat Alzheimer’s disease would best serve patients if it were introduced using gene therapy, since it involves detecting endogenous miRNAs and downregulating an endogenous enzyme (BACE1). However, gene therapy techniques such as viral vector or liposome-mediated delivery can result in serious medical complications, and other mechanisms for introducing novel genetic material into cells, such as ex vivo manipulation, also carry serious risks. Given the severity of Alzheimer’s disease and the lack of suitable treatment options for this condition, a genetic approach like ours still has the potential to improve patient outcomes and could be considered for implementation, as long as these safety concerns are taken into consideration.

Improving Biosafety with Our Synthetic B-Cell Receptor

The antibody-based sensor (synthetic B-cell receptor) that we developed to detect beta-amyloid plaques could be modified to sense other biologically relevant molecules, including those that pose a biosafety risk. By interchanging the receptor’s variable region, our sensor could be altered to detect any antigen for which there is an antibody with a known amino acid sequence. Given that our system could also be modified to produce many different types of outputs (in addition to the transcriptional activator GAL4VP16), a synthetic B-cell receptor could be of great utility for biosafety purposes and more generally as a synthetic biology tool.